Dexloxiglumide

DB04856InvestigationalSmall molecule

Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide,... As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

Mechanism: CCKA antagonists target receptors in the gastrointestinal system to increase gastric emptying and intestinal motility, as well as modulate intestinal sensitivity to distension.
Curator reviewed
Primary indication: For the treatment of Irritable Bowel Syndrome (IBS) and Gastroesophageal Reflux Disease (GERD).Curator reviewed
Formula / weight: C₂₁H₃₀Cl₂N₂O₅ · 461.379 g/mol (avg)
Code names: CR-2017

Resolves to

Compound

UNII69DY40RH9BCAS119817-90-2ChEMBLCHEMBL550781ChEBI135747PubChem65937

Structure

InChIKeyQNQZBKQEIFTHFZ-GOSISDBHSA-NSMILESCCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1

Targets

P32238CCKARP32239CCKBR

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

486Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dexloxiglumide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account